Genentech
A Member of the Roche Group

ALECENSA™
alectinib

ALECENSA® (alectinib) is NOW FDA APPROVED for the treatment of patients with anaplastic lymphoma kinase (ALK)–positive, metastatic non–small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.[1]

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

To learn more, please visit ALECENSA.com

Select Codes for Your Reference*[1,2]		
Type	**Code**	**Description**
NDC-10[1]	**50242-130-01**	240-count bottle of 150-mg capsules
NDC-11[1]	**50242-0130-01**	240-count bottle of 150-mg capsules
ICD-10[2]	**C34.00-C34.02**	Malignant neoplasm of bronchus and lung; main bronchus
	C34.10-C34.12	Malignant neoplasm of bronchus and lung; upper lobe
	C34.2	Malignant neoplasm of bronchus and lung; middle lobe
	C34.30-C34.32	Malignant neoplasm of bronchus and lung; lower lobe
	C34.80-C34.82	Malignant neoplasm of bronchus and lung; overlapping sites
	C34.90-C34.92	Malignant neoplasm of bronchus and lung; unspecified part

*Note: Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 2 months of treatment, then periodically during treatment. Based on the severity of the adverse reaction, withhold then dose reduce, or permanently discontinue ALECENSA.

Please see additional Important Safety Information in full Prescribing Information.

PATIENT ASSISTANCE INFORMATION

- Genentech BioOncology Access Solutions offers a full range of access and reimbursement support for your patients and practice to minimize delays in therapy and understand patient coverage and out-of-pocket costs
- For information, please contact Genentech BioOncology Access Solutions by calling 1-888-249-4918 or by visiting http://www.genentech-access.com/alecensa/

DISTRIBUTION INFORMATION

- ALECENSA is available through an authorized network of specialty distributors and pharmacies
- Please visit the Genentech BioOncology Access Solutions website, http://www.genentech-access.com/alecensa/, for more information on the distribution network
- For more information, please contact your BioOncology Field Reimbursement Manager

IMPORTANT SAFETY INFORMATION (CONTINUED)

Interstitial Lung Disease (ILD)/Pneumonitis: Severe ILD (Grade 3) occurred in 0.4% of patients. Immediately withhold ALECENSA in patients diagnosed with ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis have been identified.

Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold ALECENSA then dose reduce or permanently discontinue.

Severe Myalgia and Creatine Phosphokinase (CPK) Elevation: Advise patients to report any unexplained muscle pain, tenderness, or weakness. Assess CPK levels every 2 weeks for the first month of treatment and as clinically indicated in patients reporting symptoms. Based on the severity of the CPK elevation, withhold, then resume or dose reduce ALECENSA.

Embryo-Fetal Toxicity: ALECENSA can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ALECENSA and for 1 week following the final dose.

Most Common Adverse Reactions: The most common adverse reactions (incidence ≥20%) were fatigue, constipation, edema, and myalgia.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see additional Important Safety Information in full Prescribing Information.

References: 1. ALECENSA [package insert]. South San Francisco, CA: Genentech USA Inc.; 2015. **2.** ICD10Data.com. Malignant neoplasm of bronchus and lung. http://www.icd10data.com/ICD10CM/Codes/C00-D49/C30-C39/C34. Accessed July 17, 2015.

ALECENSA™ alectinib ACCESS SOLUTIONS®

Genentech
A Member of the Roche Group